News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Third HDL Selective Delipidation Patent Granted to Lipid Sciences, Inc. (LIPD)


7/1/2008 8:20:17 AM

PLEASANTON, CA--(Marketwire - July 01, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) continues to build on its already extensive HDL Selective Delipidation intellectual property portfolio with the issuance of U.S. Patent No. 7,393,826. This third patent, dated July 1, 2008, further extends the depth of patent coverage surrounding the Company's HDL Therapy platform, and in particular, the proprietary selective delipidation process. These particular patents are a critical component of the Company's strategic plan to maximize the value of this strong IP position and the recent clinical trial data to pursue a corporate partnership related to Lipid Sciences' HDL Selective Delipidation.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES